Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma [Phase 2]
Phase 2 trial evaluating activated marrow-infiltrating lymphocytes alone or with an allogeneic GM-CSF-based myeloma vaccine in autologous tr…
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma [Phase 1]
Phase 1 trial evaluating T cells targeting B-cell maturation antigen (BCMA) in previously treated multiple myeloma has completed with result…
-
FDA approval · 2019-09-26FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc., resulting in changes to the product l…
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 [Phase 1]
Phase 1 dose-escalation study evaluating safety, PK/PD, immunogenicity, and clinical activity of GSK2857916 in adults with multiple myeloma;…
-
CLINICAL_TRIALS trial_result · 2019-09-23Clinical Trial Update: Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma [Phase 2]
Phase 2 trial evaluating bortezomib with pegylated liposomal doxorubicin in previously untreated symptomatic multiple myeloma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications [Phase 1, Phase 2]
A dose-escalation Phase I study is evaluating safety and preliminary activity of a multi-indication cancer therapy in acute myeloid leukemia…
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update describes a multi-CAR T cell therapy being studied for multiple myeloma across Phase 1 and Phase 2, with the status …
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) [Phase 3]
Phase 3 trial of lenalidomide and dexamethasone with or without pembrolizumab in newly diagnosed multiple myeloma was terminated.
-
FDA approval · 2019-09-13FDA Approved: MELPHALAN HYDROCHLORIDE — Original Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved the original application for MELPHALAN HYDROCHLORIDE from Qilu Pharmaceutical Co., Ltd., granting approval of its generic produ…
-
CLINICAL_TRIALS trial_result · 2019-09-09Clinical Trial Update: Daratumumab in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial update of daratumumab in patients with plasma cell myeloma (Multiple Myeloma) completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma [Phase 2]
Phase 2 SWOG S1304 evaluated the combination of carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma; resu…
-
CLINICAL_TRIALS research · 2019-09-06Clinical Trial Update: Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Clinical trial assessing electrophysiological biomarkers of chemotherapy-related cognitive impairment and recovery; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma [Phase 2]
Phase 2 trial evaluating daratumumab in combination with DCEP for relapsed multiple myeloma with plasmacytoma.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma [Phase 2]
Phase 2 clinical trial investigating clarithromycin, lenalidomide, and dexamethasone in relapsed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) [Phase 2]
Phase 2 clinical trial investigating patients with smoldering and active multiple myeloma is currently enrolling by invitation.
-
FDA approval · 2019-08-12FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for doxorubicin hydrochloride liposome submitted by Baxter Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) [Phase 3]
Phase 3 study of pomalidomide and low-dose dexamethasone with or without pembrolizumab in relapsed/refractory multiple myeloma was terminate…
-
CLINICAL_TRIALS research · 2019-07-23Clinical Trial Update: BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating BT062 in combination with lenalidomide or pomalidomide and dexamethasone in patients with multiple myeloma; study…
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating pembrolizumab with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients eligible for stem ce…
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma [Phase 2]
Phase 2 study evaluating oral ixazomib in combination with cyclophosphamide and dexamethasone for newly diagnosed or relapsed/refractory mul…
-
CLINICAL_TRIALS trial_result · 2019-07-08Clinical Trial Update: Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for ixazomib-daratumumab without dexamethasone (IDara) in elderly patients with relapse-refractory multiple my…
-
FDA approval · 2019-07-03FDA Approved: XPOVIO — Original Application (Karyopharm Therapeutics Inc.)
The FDA approved XPOVIO (selinexor) from Karyopharm Therapeutics as a new drug application for the treatment of adult patients with relapsed…
-
CLINICAL_TRIALS trial_result · 2019-07-02Clinical Trial Update: Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma [Phase 2]
Phase 2 trial updating combination chemotherapy, peripheral stem cell transplant, biological therapy, pamidronate, and thalidomide in multip…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma [Phase 1]
Phase 1 study of GSK2816126 in relapsed/refractory B-cell and solid tumor malignancies terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma [Phase 2]
Phase 2 trial investigating nelfinavir as a drug to sensitize bortezomib in patients with myeloma not responding to proteasome inhibitors; s…